Isomark Newsletter, April 2013

Home / Isomark News / Isomark Newsletter, April 2013

April 2013

The start of this year has been very busy for Isomark. We began by securing a bridge
financing round, creating a medical advisory team, developing a regulatory pathway
and planning our commercialization strategy. We look forward to accomplishing
many milestones this year. Every few months we will update you on significant
events.

Best regards,

Joe Kremer, CEO

 

BRIDGE ROUND COMPLETED

Isomark recently completed an oversubscribed bridge round. This funding, along
with future rounds, will help to cover funding requirements for building the business
to a planned commercialization in 2015 of our breath monitoring technology. Thank
you to our new investors who joined existing investors in finalizing the round.

STATE of NEW YORK PROPOSES SEPSIS REGULATIONS

The New York Times story about a boy whose sepsis went undiagnosed and later died
has led the state of New York to propose regulations to prevent sepsis, which is
a result of an untreated infection. These regulations, which could be implemented
as soon as this year, would require hospitals to “aggressively look for sepsis so
treatment can begin sooner.” This marks a major victory both for the prevention
of sepsis and Isomark. Isomark’s non-invasive detection of metabolic changes provides
information that can often be used to identify the onset of sepsis. Follow this link
to most recent Times story.

SUCCESSFUL PATIENT TRIAL MATCHED BY PHYSICIAN’S AWARD

Isomark’s first patient study was successfully completed at the American Family
Children’s Hospital in collaboration with UW pediatric critical care physician Juan
P. Boriosi, M.D. The Isomark breath biomarker reported changes in a patient’s metabolism
48 hours before signs of sepsis were suspected using traditional methods. Boriosi’s
abstract detailing the successful trial was presented at the 2012 Midwest Society
for Pediatric Research Annual Meeting and received special recognition. Isomark
plans for future patient studies in both adult acute care and in neonates are well
underway. If you would like a review of the clinical data please contact Isomark.

To read more about Dr. Boriosi’s award and the study, click here.

ABOUT ISOMARK

Isomark’s patented non-invasive breath technology may allow for the early detection
of infection.

Isomark’s initial focus is the ICU ventilated patient.

Isomark’s technology is under development and not available for use.